Whitepaper: Development of an Efficient Manufacturing Process for Adenovirus
Posted: 18 August 2017 | Bio-Rad | No comments yet
Large-scale downstream processing of viruses for clinical applications poses challenges different from those for many other biotherapeutics. These challenges mostly arise from the size and complexity of the virus…
Here, we present purification results of a process developed for the manufacturing of a recombinant adenovirus. This two-column process results in an adenovirus preparation comparable to clinical grade products, with high yield and very low host cell protein (HCP) and DNA contamination. It is readily scalable, simple, rapid, and efficient and thus well-suited for the production of clinical grade viral vectors.
Related content from this organisation
- Transfection technologies market to value $1.5 billion by 2026
- Viral vector purification market expected to reach over $1 billion by 2028
- Scientific Poster & Whitepaper Gallery 2019
- Scientific poster: Nuvia aPrime 4A: a hydrophobic anion exchange resin for refined selectivity and recovery
- Scientific Poster & Whitepaper Gallery 2018
Related topics
Biopharmaceuticals, Drug Development, Drug Manufacturing, Manufacturing, Viruses